Collegium Pharmaceutical, Inc. Common Stock
Veridion Score
Composite trend over time
Why is COLL moving today?
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for COLL.
COLL insider activity
Collegium Pharmaceutical, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for COLL.
COLL contract awards, year to date.
Public federal awards linked to this ticker.
COLL lobbying filings, year to date.
Registered lobbying filings matched to Collegium Pharmaceutical, Inc. Common Stock.